High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors

Korean Journal of Pediatrics. 2013;56(9):401-406 DOI 10.3345/kjp.2013.56.9.401

 

Journal Homepage

Journal Title: Korean Journal of Pediatrics

ISSN: 1738-1061 (Print); 2092-7258 (Online)

Publisher: Korean Pediatric Society

LCC Subject Category: Medicine: Pediatrics

Country of publisher: Korea, Republic of

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


Juhee Seo (Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.)

Dong Ho Kim (Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.)

Jung Sub Lim (Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.)

Jae-Soo Koh (Department of Pathology, Korea Cancer Center Hospital, Seoul, Korea.)

Ji Young Yoo (Department of Diagnostic Radiology, Korea Cancer Center Hospital, Seoul, Korea.)

Chang-Bae Kong (Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea.)

Won Seok Song (Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea.)

Wan Hyeong Cho (Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea.)

Dae-Geun Jeon (Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea.)

Soo-Yong Lee (Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea.)

Jun Ah Lee (Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.)

EDITORIAL INFORMATION

Peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 12 weeks

 

Abstract | Full Text

PurposeWe performed a pilot study to determine the benefit of high-dose chemotherapy and autologous peripheral blood stem cell transplantation (HDCT/autoPBSCT) for patients with Ewing sarcoma family of tumors.MethodsWe retrospectively analyzed the data of patients who received HDCT/autoPBSCT at Korea Cancer Center Hospital. Patients with relapsed, metastatic, or centrally located tumors were eligible for the study.ResultsA total of 9 patients (3 male, 6 female), with a median age at HDCT/autoPBSCT of 13.4 years (range, 7.1 to 28.2 years), were included in this study. Patients underwent conventional chemotherapy and local control either by surgery or radiation therapy, and had achieved complete response (CR, n=7), partial response (n=1), or stable disease (n=1) prior to HDCT/autoPBSCT. There was no transplant-related mortality. However, the median duration of overall survival and event-free survival after HDCT/autoPBSCT were 13.3 months (range, 5.3 to 44.5 months) and 6.2 months (range, 2.1 to 44.5 months), respectively. At present, 4 patients are alive and 5 patients who experienced adverse events (2 metastasis, 2 local recur, and 1 progressive disease) survived for a median time of 2.8 months (range, 0.1 to 10.7 months). The 2-year survival after HDCT/autoPBSCT was 44.4%±16.6% and disease status at the time of HDCT/autoPBSCT tended to influence survival (57.1%±18.7% of cases with CR vs. 0% of cases with non-CR, P=0.07).ConclusionDisease status at HDCT/autoPBSCT tended to influence survival. Further studies are necessary to define the role of HDCT/autoPBSCT and to identify subgroup of patients who might benefit from this investigational treatment.